Text Size
43 studies found for:    "Alpha 1-antitrypsin deficiency"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
21 Active, not recruiting Extension Study of Zemaira i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.
Conditions: Emphysema;   Alpha 1-proteinase Inhibitor Deficiency
Intervention: Biological: Alpha 1- proteinase inhibitor [human]
22 Completed
Has Results 		Pharmacokinetic Study of ARALAST (Human Alpha1- PI)
Condition: Alpha 1-Antitrypsin Deficiency
Interventions: Biological: Dose of 60 mg/kg Fraction IV-1 Alpha1-Proteinase Inhibitor;   Biological: Dose of 60 mg/kg alpha1-proteinase inhibitor
23 Completed Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor (API) Deficiency
Conditions: Alpha1-proteinase Inhibitor Deficiency;   Emphysema
Interventions: Biological: Alpha1-proteinase inhibitor;   Other: Placebo
24 Completed 4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency?
Condition: Alpha 1-Antitrypsin Deficiency
Intervention: Drug: 4 Phenyl Butyrate (4PBA)
25 Completed Alpha1-Antitrypsin Deficiency Registry
Conditions: Lung Diseases;   Emphysema;   Alpha-1 Antitrypsin Deficiency;   Chronic Obstructive Pulmonary Disease
Intervention:
26 Recruiting Alpha-1 Foundation Research Registry
Condition: Alpha 1-Antitrypsin Deficiency
Intervention:
27 Completed Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals
Conditions: Emphysema;   Lung Diseases, Obstructive;   Alpha 1-Antitrypsin Deficiency
Intervention:
28 Completed The Safety and Tolerability of Alpha-1 MP In Subjects With Alpha-1-Antitrypsin (AAT) Deficiency
Condition: Alpha 1-Antitrypsin Deficiency
Intervention: Drug: alpha-1 proteinase inhibitor (human)
29 Recruiting Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.
Condition: Alpha 1 Antitrypsin Deficiency
Intervention: Drug: Alpha-1 Antitrypsin (human)
30 Recruiting Alpha-1 Coded Testing(ACT) Study
Condition: Alpha-1 Antitrypsin Deficiency
Intervention: Procedure: Alpha-1 Antitrypsin Genotype
31 Completed GLASSIA Infusion Rate Study
Conditions: Alpha1-antitrypsin Deficiency;   Healthy
Interventions: Biological: Alpha1-proteinase inhibitor;   Biological: Placebo: Human albumin 2.5%
32 Recruiting Evaluating the Genetic Causes and Progression of Cholestatic Liver Diseases (LOGIC)
Conditions: Liver Diseases;   Alagille Syndrome;   Alpha 1-Antitrypsin Deficiency
Intervention:
33 Completed Safety Study of Alfalastin (Human Alpha-1 Antitrypsin) Administered at Home
Condition: Alpha 1-Antitrypsin Deficiency
Intervention:
34 Active, not recruiting Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability
Conditions: Emphysema;   Chronic Obstructive Pulmonary Disease (COPD);   Cystic Fibrosis;   Pulmonary Fibrosis;   Bronchiectasis;   Sarcoidosis;   Pulmonary Hypertension;   Alpha-1 Antitrypsin Deficiency
Interventions: Procedure: Transplantation of Lungs After Ex-vivo Perfusion w/ STEEN Solution™;   Device: Steen Solution™
35 Not yet recruiting Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
Conditions: Emphysema;   Chronic Obstructive Pulmonary Disease (COPD);   Cystic Fibrosis;   Pulmonary Fibrosis;   Bronchiectasis;   Sarcoidosis;   Pulmonary Hypertension;   Alpha-1 Antitrypsin Deficiency
Interventions: Procedure: Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™;   Device: STEEN Solution™
36 Enrolling by invitation Alpha-1 Foundation DNA and Tissue Bank
Condition: Alpha 1 Antitrypsin Deficiency
Intervention:
37 Recruiting Polygen Defi-Alpha: Genetic Polymorphisms Study in Children With Alpha-1 Antitrypsin Deficiency, Included in the DEFI-ALPHA Cohort
Condition: Children With a Deficiency of Alpha-1 Antitrypsin
Intervention: Other: blood sampling
38 Terminated
Has Results 		Aralast alpha1-proteinase Inhibitor Surveillance Study
Condition: Alpha 1-Antitrypsin (AAT) Deficiency
Intervention: Drug: ARALAST Alpha1-Proteinase Inhibitor
39 Completed Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic Fibrosis
Condition: Cystic Fibrosis
Interventions: Biological: CR002 Liquid API;   Biological: Placebo
40 Recruiting Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis
Condition: Cystic Fibrosis
Interventions: Biological: Alpha-1 HC;   Biological: Placebo
To Top

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-43) Show next page of results
† Indicates status has not been verified in more than two years